Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A GlaxoSmithKline allergy medicine currently under review by the FDA, was effective and well-tolerated in treating a range of nasal allergy symptoms such as congestion, sneezing, itchy and runny nose, according to phase III clinical studies.
Subscribe to our email newsletter
In two separate phase III studies, fluticasone furoate nasal spray (FFNS) was more effective than placebo in relieving both the nasal and eye symptoms of patients 12 years and older with seasonal allergic rhinitis, commonly known as hay fever.
One additional phase III study among individuals with perennial allergic rhinitis (year-round nasal allergies) found FFNS to be more effective than placebo in relieving nasal symptoms. Moreover, the symptom-relief lasted 24 hours in all three studies.
“These are the first two prospectively-designed phase III studies to demonstrate consistent and significant improvement in eye-related allergy symptoms with an intranasal steroid,” commented lead investigator William Lumry, Asthma & Allergy Specialists, Dallas.